Janney Montgomery Scott LLC Lowers Stock Position in Edwards Lifesciences Corporation $EW

Janney Montgomery Scott LLC lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,565 shares of the medical research company’s stock after selling 296 shares during the period. Janney Montgomery Scott LLC’s holdings in Edwards Lifesciences were worth $3,329,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC raised its holdings in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Edwards Lifesciences by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at about $330,881,000. Invesco Ltd. raised its holdings in shares of Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after purchasing an additional 198,882 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Monday, September 22nd. Finally, Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.06.

Edwards Lifesciences Trading Down 1.3%

Shares of Edwards Lifesciences stock opened at $75.75 on Thursday. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The firm has a market cap of $44.47 billion, a PE ratio of 10.90, a PEG ratio of 3.69 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a 50 day simple moving average of $78.28 and a two-hundred day simple moving average of $76.05.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.70 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.